NSE:CIPLA News 7 January 2026 - 23 January 2026

Mumbai, Jan 7, 2026, 12:33 IST Shares of Cipla were down 4.6% at 1,460.2 rupees by midday on Wednesday after the U.S. Food and Drug Administration published inspection observations for Pharmathen International S.A., a contract manufacturer linked to the Indian drugmaker’s U.S. supply chain. The Economic Times The disclosure matters because Pharmathen is a key manufacturing partner for Cipla’s lanreotide product in the United States, an area investors track closely for growth and margins. Any compliance overhang at a third-party plant can tighten supply, delay launches and force costly workarounds. Angel One FDA inspectors use a Form 483 to document